JP2000504925A5 - - Google Patents

Download PDF

Info

Publication number: JP2000504925A5
Authority: JP; Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

JP1997515329A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000504925A (ja

Filing date

1996-10-25

Publication date

2004-10-14

1996-01-11 Priority claimed from US08/584,040 external-priority patent/US6346398B1/en

1996-10-25 Application filed filed Critical

2000-04-25 Publication of JP2000504925A publication Critical patent/JP2000504925A/ja

2004-10-14 Publication of JP2000504925A5 publication Critical patent/JP2000504925A5/ja

Status Ceased legal-status Critical Current

Links

JP9515329A 1995-10-26 1996-10-25 血管内皮増殖因子レセプターのレベルに関連する疾患または病状を治療するための方法および薬剤 Ceased JP2000504925A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US597495P	1995-10-26	1995-10-26
US08/584,040		1996-01-11
US60/005,974		1996-01-11
US08/584,040 US6346398B1 (en)	1995-10-26	1996-01-11	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
PCT/US1996/017480 WO1997015662A2 (en)	1995-10-26	1996-10-25	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

Publications (2)

Publication Number	Publication Date
JP2000504925A JP2000504925A (ja)	2000-04-25
JP2000504925A5 true JP2000504925A5 (2)	2004-10-14

Family

ID=26674998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9515329A Ceased JP2000504925A (ja)	1995-10-26	1996-10-25	血管内皮増殖因子レセプターのレベルに関連する疾患または病状を治療するための方法および薬剤

Country Status (7)

Country	Link
US (5)	US6346398B1 (2)
EP (1)	EP0859837A2 (2)
JP (1)	JP2000504925A (2)
AU (1)	AU7666296A (2)
CA (1)	CA2235368A1 (2)
DE (1)	DE69638198D1 (2)
WO (1)	WO1997015662A2 (2)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0642589A4 (en) *	1992-05-11	1997-05-21	Ribozyme Pharm Inc	METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US20030206887A1 (en) *	1992-05-14	2003-11-06	David Morrissey	RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US6710174B2 (en) *	2001-09-13	2004-03-23	Isis Pharmaceuticals, Inc.	Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US5639647A (en) *	1994-03-29	1997-06-17	Ribozyme Pharmaceuticals, Inc.	2'-deoxy-2'alkylnucleotide containing nucleic acid
US6346398B1 (en) *	1995-10-26	2002-02-12	Ribozyme Pharmaceuticals, Inc.	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US20040220128A1 (en) *	1995-10-26	2004-11-04	Sirna Therapeutics, Inc.	Nucleic acid based modulation of female reproductive diseases and conditions
US20040142895A1 (en) *	1995-10-26	2004-07-22	Sirna Therapeutics, Inc.	Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
JP2002511734A (ja) *	1996-11-21	2002-04-16	シーダーズ―サイナイ・メディカル・センター	下垂体―腫瘍―形質転換遺伝子及び関連生成物
US7097829B2 (en) *	1996-11-21	2006-08-29	Cedars-Sinai Medical Center	Transgenic cells transfected with pituitary tumor transforming gene (PTTG)) expression vectors and uses therefor
US6894031B1 (en) *	1996-11-21	2005-05-17	Cedars-Sinai Medical Center	Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
US20050096282A1 (en) *	1997-04-21	2005-05-05	Lewin Alfred S.	Adeno-associated virus-delivered ribozyme compositions and methods for the treatment of retinal diseases
EP1321521A1 (en) *	1997-05-09	2003-06-25	Ribozyme Pharmaceuticals, Inc.	Ribozymes directed against flt-1
CA2301166A1 (en) *	1997-07-24	1999-02-04	Yuan-Peng Zhang	Liposomal compositions for the delivery of nucleic acid catalysts
US7973156B2 (en) *	1997-08-21	2011-07-05	Quark Pharmaceuticals Inc.	Hypoxia-regulated genes
US20030104973A1 (en) *	1997-08-21	2003-06-05	Quark Biotech, Inc.	Hypoxia-regulated genes
US6518017B1 (en) *	1997-10-02	2003-02-11	Oasis Biosciences Incorporated	Combinatorial antisense library
EP1086212A2 (en) *	1998-03-27	2001-03-28	Ribozyme Pharmaceuticals, Inc.	Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses
AU3751299A (en) *	1998-04-20	1999-11-08	Ribozyme Pharmaceuticals, Inc.	Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6417169B1 (en) *	1998-04-23	2002-07-09	Genesense Technologies Inc.	Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US7087580B2 (en)	1998-04-23	2006-08-08	Genesense Technologies, Inc.	Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
CA2328893A1 (en) *	1998-05-20	1999-11-25	Kyowa Hakko Kogyo Co., Ltd.	Vegf activity inhibitors
TR200102278T2 (tr) *	1998-11-06	2001-12-21	Basf Aktiengesellschaft	Vasküler hiperpermeabilite oluşumunun önlenmesi.
AUPP795198A0 (en) *	1998-12-24	1999-01-28	Commonwealth Scientific And Industrial Research Organisation	Miniribozymes active at low magnesium ion concentrations
DE19956568A1 (de) *	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2001018209A1 (en) *	1999-09-10	2001-03-15	Curagen Corporation	Fibroblast growth factor polypeptide and nucleic acids encoding same
WO2001023616A2 (en) *	1999-09-29	2001-04-05	Genetic Vectors, Inc.	Method of identifying pathogenic cryptococci
US7829693B2 (en) *	1999-11-24	2010-11-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a target gene
US20050032733A1 (en) *	2001-05-18	2005-02-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US20080039414A1 (en) *	2002-02-20	2008-02-14	Sima Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8273866B2 (en) *	2002-02-20	2012-09-25	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) *	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2002081628A2 (en) *	2001-04-05	2002-10-17	Ribozyme Pharmaceuticals, Incorporated	Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
NZ524894A (en) *	2000-09-02	2005-03-24	Gruenenthal Chemie	Antisense oligonucleotides against VR1
US7125660B2 (en) *	2000-09-13	2006-10-24	Archemix Corp.	Nucleic acid sensor molecules and methods of using same
US20030186920A1 (en) *	2000-10-13	2003-10-02	Sirois Martin G.	Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
DE60137273D1 (de) *	2000-10-20	2009-02-12	Eisai R&D Man Co Ltd	Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
US8546143B2 (en)	2001-01-09	2013-10-01	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a target gene
DE10106370B4 (de) *	2001-02-12	2005-01-27	Vermicon Ag	Oligonukleotidsonden zur Detektion von parodontopathogenen Bakterien mittels in situ-Hybridisierung
US20030171310A1 (en) *	2001-02-23	2003-09-11	Isis Pharmaceuticals Inc.	Antisense modulation of RECQL expression
US20030224365A1 (en) *	2001-04-24	2003-12-04	Wood Linda Susan	Single nucleotide polymorphisms diagnostic for schizophrenia
US20050124567A1 (en) *	2001-05-18	2005-06-09	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US20040209831A1 (en) *	2002-02-20	2004-10-21	Mcswiggen James	RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) *	2001-05-18	2005-08-18	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
WO2002097114A2 (en) *	2001-05-29	2002-12-05	Sirna Therapeutics, Inc.	Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US20040019001A1 (en) *	2002-02-20	2004-01-29	Mcswiggen James A.	RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20050176025A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20080188430A1 (en) *	2001-05-18	2008-08-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050136436A1 (en) *	2001-05-18	2005-06-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) *	2001-05-18	2008-07-03	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050153914A1 (en) *	2001-05-18	2005-07-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US20050196781A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
US20050261219A1 (en) *	2001-05-18	2005-11-24	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050176663A1 (en) *	2001-05-18	2005-08-11	Sima Therapeutics, Inc.	RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) *	2002-02-20	2005-03-03	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20060142225A1 (en) *	2001-05-18	2006-06-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) *	2001-05-18	2006-09-21	Sirna Therapeutics, Inc.	RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050164966A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) *	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) *	2001-05-18	2005-12-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) *	2001-05-18	2005-09-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) *	2001-11-30	2004-10-07	Mcswiggen James	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
WO2005078097A2 (en) *	2004-02-10	2005-08-25	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
US20050187174A1 (en) *	2001-05-18	2005-08-25	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) *	2001-05-18	2006-10-26	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20050164967A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20050267058A1 (en) *	2001-05-18	2005-12-01	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US20050124569A1 (en) *	2001-05-18	2005-06-09	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US20090299045A1 (en) *	2001-05-18	2009-12-03	Sirna Therapeutics, Inc.	RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20050222066A1 (en) *	2001-05-18	2005-10-06	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050191618A1 (en) *	2001-05-18	2005-09-01	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) *	2001-05-18	2005-06-09	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050164224A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20070042983A1 (en) *	2001-05-18	2007-02-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050159380A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20070093437A1 (en) *	2001-05-18	2007-04-26	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
US20050256068A1 (en) *	2001-05-18	2005-11-17	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050159379A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc	RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) *	2002-02-20	2005-01-20	Ivan Richards	RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) *	2001-05-18	2005-06-02	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) *	2001-05-18	2006-09-19	Sirna Therapeutics, Inc.	Conjugates and compositions for cellular delivery
US20050176664A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050079610A1 (en) *	2001-05-18	2005-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050137155A1 (en) *	2001-05-18	2005-06-23	Sirna Therapeutics, Inc.	RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050196767A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
WO2003070910A2 (en) *	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Incorporated	INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20070270579A1 (en) *	2001-05-18	2007-11-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) *	2001-05-18	2005-09-15	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) *	2001-05-18	2005-06-30	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050158735A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) *	2002-02-20	2005-07-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20050277133A1 (en) *	2001-05-18	2005-12-15	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
CA2448320A1 (en) *	2001-05-29	2002-12-05	Sirna Therapeutics, Inc.	Ribozyme based treatment of female reproductive diseases
EP1767632A3 (en) *	2001-05-29	2009-12-30	Sirna Therpeutics, Inc.	A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor
WO2003006059A1 (en) *	2001-07-13	2003-01-23	Imclone Systems Incorporated	Vegfr-1 antibodies to treat breast cancer
US7968523B2 (en) *	2001-07-23	2011-06-28	Senesco Technologies, Inc.	Method for inducing apoptosis using apoptosis-specific EIF5-A
US6734017B2 (en) *	2001-09-28	2004-05-11	Isis Pharmaceuticals, Inc.	Antisense modulation of vascular endothelial growth factor receptor-2 expression
US6909030B2 (en) *	2001-10-15	2005-06-21	Cedars-Sinai Medical Center	PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes
US20040138163A1 (en) *	2002-05-29	2004-07-15	Mcswiggen James	RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070203333A1 (en) *	2001-11-30	2007-08-30	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2006203062B2 (en) *	2002-02-20	2009-03-12	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1474433A4 (en) *	2002-02-20	2005-02-23	Sirna Therapeutics Inc	TARGET LOCALIZATION TARGETED BY RNA INTERFERENCE AND TARGET VALIDATION WITH SHORT INTERFERING NUCLEIC ACID (siNA)
US7700760B2 (en)	2002-02-20	2010-04-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050096284A1 (en) *	2002-02-20	2005-05-05	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
WO2003106476A1 (en) *	2002-02-20	2003-12-24	Sirna Therapeutics, Inc	Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
GB2397062B (en) *	2002-02-20	2005-06-15	Sirna Therapeutics Inc	RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
US7667030B2 (en) *	2002-02-20	2010-02-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
BR0313550A (pt) *	2002-08-14	2006-06-13	Pharmacia Corp	modulação "antisense" da expressão de sintetase 1 de acil-coa
US7956176B2 (en)	2002-09-05	2011-06-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040077567A1 (en) *	2002-10-16	2004-04-22	Isis Pharmaceuticals Inc.	Antisense modulation of CD36 expression
US20040076621A1 (en) *	2002-10-16	2004-04-22	Isis Pharmaceuticals Inc.	Antisense modulation of CD36 expression
US9771586B2 (en)	2002-11-14	2017-09-26	Thermo Fisher Scientific Inc.	RNAi targeting ZNF205
US9719092B2 (en)	2002-11-14	2017-08-01	Thermo Fisher Scientific Inc.	RNAi targeting CNTD2
US7781575B2 (en)	2002-11-14	2010-08-24	Dharmacon, Inc.	siRNA targeting tumor protein 53 (p53)
US7951935B2 (en)	2002-11-14	2011-05-31	Dharmacon, Inc.	siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
WO2006006948A2 (en) *	2002-11-14	2006-01-19	Dharmacon, Inc.	METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7592442B2 (en) *	2002-11-14	2009-09-22	Dharmacon, Inc.	siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US10011836B2 (en)	2002-11-14	2018-07-03	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en)	2002-11-14	2017-12-12	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en)	2002-11-14	2017-08-01	Thermo Fisher Scientific Inc.	RNAi targeting SEC61G
US7612196B2 (en) *	2002-11-14	2009-11-03	Dharmacon, Inc.	siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
EP2305812A3 (en) *	2002-11-14	2012-06-06	Dharmacon, Inc.	Fuctional and hyperfunctional sirna
US7635770B2 (en) *	2002-11-14	2009-12-22	Dharmacon, Inc.	siRNA targeting protein kinase N-3 (PKN-3)
US20100113307A1 (en) *	2002-11-14	2010-05-06	Dharmacon, Inc.	siRNA targeting vascular endothelial growth factor (VEGF)
US9879266B2 (en)	2002-11-14	2018-01-30	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US8198427B1 (en)	2002-11-14	2012-06-12	Dharmacon, Inc.	SiRNA targeting catenin, beta-1 (CTNNB1)
US7691998B2 (en) *	2002-11-14	2010-04-06	Dharmacon, Inc.	siRNA targeting nucleoporin 62kDa (Nup62)
US20090227780A1 (en) *	2002-11-14	2009-09-10	Dharmacon, Inc.	siRNA targeting connexin 43
US9228186B2 (en)	2002-11-14	2016-01-05	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
ATE508747T1 (de) *	2003-03-10	2011-05-15	Eisai R&D Man Co Ltd	C-kit kinase-hemmer
CA2518912A1 (en) *	2003-03-12	2004-09-23	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20070270360A1 (en) *	2003-04-15	2007-11-22	Sirna Therapeutics, Inc.	Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
CN1780920B (zh) *	2003-05-12	2012-03-28	波多玛克制药有限公司	基因表达抑制剂
CN100375750C (zh) *	2003-05-15	2008-03-19	中国疾病预防控制中心病毒病预防控制所	抑制人肿瘤坏死因子活性的寡聚核苷酸
US7683172B2 (en) *	2003-11-11	2010-03-23	Eisai R&D Management Co., Ltd.	Urea derivative and process for preparing the same
US20060019914A1 (en) *	2004-02-11	2006-01-26	University Of Tennessee Research Foundation	Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
WO2005097817A2 (en)	2004-04-05	2005-10-20	Alnylam Pharmaceuticals, Inc.	Process and reagents for oligonucleotide synthesis and purification
AU2005325262B2 (en)	2004-04-27	2011-08-11	Alnylam Pharmaceuticals, Inc.	Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
US20060182783A1 (en) *	2004-04-30	2006-08-17	Allergan, Inc.	Sustained release intraocular drug delivery systems
US7674778B2 (en)	2004-04-30	2010-03-09	Alnylam Pharmaceuticals	Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
US8591885B2 (en)	2004-04-30	2013-11-26	Allergan, Inc.	Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2572151A1 (en)	2004-06-30	2006-08-24	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a non-phosphate backbone linkage
AU2005328382C1 (en)	2004-07-21	2013-01-24	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a modified or non-natural nucleobase
CA2574603C (en)	2004-08-04	2014-11-04	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
AU2005283422C1 (en)	2004-09-17	2017-02-02	Eisai R & D Management Co., Ltd.	Medicinal composition
EP1799867A2 (en) *	2004-09-23	2007-06-27	Vasgene Therapeutics, Inc.	Compositions and methods for detecting and treating tumors
US20060099618A1 (en) *	2004-09-30	2006-05-11	Innogenetics, N.V.	Detection, identification and differentiation of Serratia species using the spacer region
JP4131271B2 (ja) *	2005-03-30	2008-08-13	ソニー株式会社	情報処理装置および方法、並びにプログラム
JP2008537752A (ja) *	2005-04-12	2008-09-25	イントラディグムコーポレイション	がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US7893244B2 (en) *	2005-04-12	2011-02-22	Intradigm Corporation	Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1925941B1 (en) *	2005-08-01	2012-11-28	Eisai R&D Management Co., Ltd.	Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja)	2005-08-02	2007-02-08	Eisai R & D Management Co., Ltd.	血管新生阻害物質の効果を検定する方法
US20090176725A1 (en) *	2005-08-17	2009-07-09	Sirna Therapeutics Inc.	Chemically modified short interfering nucleic acid molecules that mediate rna interference
CA2620594C (en) *	2005-09-01	2012-08-21	Eisai R&D Management Co., Ltd.	Pharmaceutical composition having improved disintegratability
US8168584B2 (en)	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN101316590B (zh) *	2005-11-07	2011-08-03	卫材R&D管理有限公司	血管生成抑制剂和c-kit激酶抑制剂的组合使用
WO2007061130A1 (ja) *	2005-11-22	2007-05-31	Eisai R & D Management Co., Ltd.	多発性骨髄腫に対する抗腫瘍剤
RU2448708C3 (ru) *	2006-05-18	2017-09-28	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое средство против рака щитовидной железы
EP2044939A1 (en) *	2006-06-29	2009-04-08	Eisai R&D Management Co., Ltd.	Therapeutic agent for liver fibrosis
CN101511793B (zh) *	2006-08-28	2011-08-03	卫材R&D管理有限公司	针对未分化型胃癌的抗肿瘤剂
US8039010B2 (en) *	2006-11-03	2011-10-18	Allergan, Inc.	Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8586556B2 (en)	2006-11-03	2013-11-19	Allergan, Inc.	Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
CN101600694A (zh) *	2007-01-29	2009-12-09	卫材R&D管理有限公司	未分化型胃癌治疗用组合物
WO2008103471A2 (en)	2007-02-23	2008-08-28	The Trustees Of Columbia University In The City Of New York	Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
US11078262B2 (en)	2007-04-30	2021-08-03	Allergan, Inc.	High viscosity macromolecular compositions for treating ocular conditions
WO2009014766A2 (en) *	2007-07-26	2009-01-29	The University Of Utah Research Foundation	Non-invasive recovery of rna and analysis of gene expression in skin
WO2009051659A2 (en) *	2007-10-12	2009-04-23	Intradigm Corporation	Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
KR101513326B1 (ko)	2007-11-09	2015-04-17	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 신생 저해 물질과 항종양성 백금 착물의 병용
AU2009210098B2 (en) *	2008-01-29	2013-06-13	Eisai R & D Management Co., Ltd.	Combined use of angiogenesis inhibitor and taxane
US20090226531A1 (en) *	2008-03-07	2009-09-10	Allergan, Inc.	Methods and composition for intraocular delivery of therapeutic sirna
JP2011526892A (ja)	2008-06-30	2011-10-20	アンジオブラストシステムズ，インコーポレーテッド	併用療法を使用した眼疾患及び過剰血管新生の治療
DK2468281T3 (en)	2009-08-19	2016-03-21	Eisai R&D Man Co Ltd	Quinolinderivatholdig pharmaceutical composition
US9799416B2 (en) *	2009-11-06	2017-10-24	Terrapower, Llc	Methods and systems for migrating fuel assemblies in a nuclear fission reactor
US8618071B2 (en) *	2010-05-21	2013-12-31	Industrial Technology Research Institute	Oligonucleotides for suppressing cancer cell invasion and migration
WO2011162343A1 (ja)	2010-06-25	2011-12-29	エーザイ・アール・アンド・ディー・マネジメント株式会社	キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
CN103402519B (zh)	2011-04-18	2015-11-25	卫材R&D管理有限公司	肿瘤治疗剂
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
ES2879430T3 (es)	2012-11-15	2021-11-22	Apellis Pharmaceuticals Inc	Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
AU2013364953A1 (en)	2012-12-21	2015-04-30	Eisai R&D Management Co., Ltd.	Amorphous form of quinoline derivative, and method for producing same
WO2014152391A1 (en)	2013-03-15	2014-09-25	Apellis Pharmaceuticals, Inc.	Cell-penetrating compstatin analogs and uses thereof
EP2997377B1 (en)	2013-05-14	2018-07-18	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103627709A (zh) *	2013-12-06	2014-03-12	孙仑泉	抑制血管内皮生长因子受体基因表达的脱氧核酶
PT3524595T (pt)	2014-08-28	2022-09-19	Eisai R&D Man Co Ltd	Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en)	2015-02-25	2021-06-03	Eisai R&D Management Co., Ltd.	Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104831788A (zh) *	2015-05-08	2015-08-12	济南宏泰疏通技术有限公司	一种保护软轴疏通的装置
BR112017027227B1 (pt)	2015-06-16	2023-12-12	Eisai R&D Management Co., Ltd	Agente anti-câncer
JP6553726B2 (ja)	2015-08-20	2019-07-31	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
EP3359555B1 (en)	2015-10-07	2023-12-20	Apellis Pharmaceuticals, Inc.	Dosing regimens
EP4035659A1 (en)	2016-11-29	2022-08-03	PureTech LYT, Inc.	Exosomes for delivery of therapeutic agents
JP6581320B2 (ja)	2017-02-08	2019-09-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療用医薬組成物
JP2020516607A (ja)	2017-04-07	2020-06-11	アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	投与レジメンならびに関連組成物および方法
NO344051B1 (en) *	2017-05-04	2019-08-26	Patogen As	Novel virus in Fish and Method for detection
EP3624800A4 (en)	2017-05-16	2021-02-17	Eisai R&D Management Co., Ltd.	TREATMENT OF HEPATOCELLULAR CARCINOMA
AU2018386304B2 (en)	2017-12-15	2023-12-07	Apellis Pharmaceuticals, Inc.	Dosing regimens and related compositions and methods

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340323C (en)	1988-09-20	1999-01-19	Arnold E. Hampel	Rna catalyst for cleaving specific rna sequences
AU637800B2 (en)	1989-08-31	1993-06-10	City Of Hope	Chimeric dna-rna catalytic sequences
US5359051A (en)	1990-01-11	1994-10-25	Isis Pharmaceuticals	Compounds useful in the synthesis of nucleic acids capable of cleaning RNA
JP3257675B2 (ja)	1990-10-12	2002-02-18	マックス−プランク−ゲゼルシャフトツールフェルデルングデルビッセンシャフテンエー．ファウ．	修飾リボザイム
DE4216134A1 (de)	1991-06-20	1992-12-24	Europ Lab Molekularbiolog	Synthetische katalytische oligonukleotidstrukturen
US5218285A (en)	1991-12-16	1993-06-08	Motorola, Inc.	Electronic device with dual purpose regulator
US5652094A (en)	1992-01-31	1997-07-29	University Of Montreal	Nucleozymes
EP0642589A4 (en)	1992-05-11	1997-05-21	Ribozyme Pharm Inc	METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5496698A (en) *	1992-08-26	1996-03-05	Ribozyme Pharmaceuticals, Inc.	Method of isolating ribozyme targets
JPH08502950A (ja)	1992-05-14	1996-04-02	リボザイム・ファーマシューティカルズ・インコーポレイテッド	癌増殖を抑制する方法及び試薬
US5525468A (en) *	1992-05-14	1996-06-11	Ribozyme Pharmaceuticals, Inc.	Assay for Ribozyme target site
WO1994002595A1 (en)	1992-07-17	1994-02-03	Ribozyme Pharmaceuticals, Inc.	Method and reagent for treatment of animal diseases
CN1701814A (zh)	1992-11-13	2005-11-30	马克斯普朗克科学促进协会	作为血管内皮生长因子受体的f1k－1
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO1994021791A1 (en) *	1993-03-16	1994-09-29	Johanna Eugenie Bergmann	Agents for the prevention and treatment of breast cancer
AU684498B2 (en)	1993-03-25	1997-12-18	Merck & Co., Inc.	Inhibitor of vascular endothelial cell growth factor
US6410322B1 (en)	1993-07-27	2002-06-25	Hybridon Inc	Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
WO1995004818A1 (en)	1993-08-06	1995-02-16	Ribozyme Pharmaceuticals, Inc.	Method and reagent for inhibiting human immunodeficiency virus replication
US5861288A (en)	1993-10-18	1999-01-19	Ribozyme Pharmaceuticals, Inc.	Catalytic DNA
US5510239A (en) *	1993-10-18	1996-04-23	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of multidrug resistance-associated protein
DE69431564D1 (de)	1993-11-12	2002-11-21	Ribozyme Pharm Inc	Reagenz zur behandlung von arthritischen zustaenden
US5840301A (en)	1994-02-10	1998-11-24	Imclone Systems Incorporated	Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5631359A (en)	1994-10-11	1997-05-20	Ribozyme Pharmaceuticals, Inc.	Hairpin ribozymes
CA2183992A1 (en)	1994-02-23	1995-08-31	Dan T. Stinchcomb	Method and reagent for inhibiting the expression of disease related genes
US5885613A (en)	1994-09-30	1999-03-23	The University Of British Columbia	Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en)	1994-09-30	1998-05-19	Inex Pharmaceuticals Corporation	Compositions for the introduction of polyanionic materials into cells
US5820873A (en)	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5872241A (en)	1995-01-25	1999-02-16	The Trustees Of Columbia University In The City Of New York	Multiple component RNA catalysts and uses thereof
CA2225460A1 (en) *	1995-06-23	1997-01-09	Winston Campbell Patterson	Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6346398B1 (en) *	1995-10-26	2002-02-12	Ribozyme Pharmaceuticals, Inc.	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
DE69637256T2 (de)	1996-01-16	2008-06-19	Sirna Therapeutics, Inc., Boulder	Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
US5849902A (en)	1996-09-26	1998-12-15	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
ATE342911T1 (de)	1996-12-24	2006-11-15	Sirna Therapeutics Inc	Synthese von nukleosiden und polynukleotiden
CA2295207A1 (en)	1997-06-19	1998-12-23	Innovir Laboratories, Inc.	Hammerhead ribozymes with extended cleavage rule
CA2301166A1 (en)	1997-07-24	1999-02-04	Yuan-Peng Zhang	Liposomal compositions for the delivery of nucleic acid catalysts
CA2304813A1 (en)	1997-09-22	1999-04-08	Fritz Eckstein	Nucleic acid catalysts with endonuclease activity
US7148342B2 (en) *	2002-07-24	2006-12-12	The Trustees Of The University Of Pennyslvania	Compositions and methods for sirna inhibition of angiogenesis

1996
- 1996-01-11 US US08/584,040 patent/US6346398B1/en not_active Expired - Lifetime
- 1996-10-25 DE DE69638198T patent/DE69638198D1/de not_active Expired - Lifetime
- 1996-10-25 JP JP9515329A patent/JP2000504925A/ja not_active Ceased
- 1996-10-25 WO PCT/US1996/017480 patent/WO1997015662A2/en not_active Ceased
- 1996-10-25 EP EP96939515A patent/EP0859837A2/en not_active Ceased
- 1996-10-25 AU AU76662/96A patent/AU7666296A/en not_active Abandoned
- 1996-10-25 CA CA002235368A patent/CA2235368A1/en not_active Abandoned
1999
- 1999-08-10 US US09/371,772 patent/US6566127B1/en not_active Expired - Fee Related
2000
- 2000-10-10 US US09/685,664 patent/US6818447B1/en not_active Expired - Lifetime
2004
- 2004-09-27 US US10/951,303 patent/US20050227937A1/en not_active Abandoned
2008
- 2008-07-09 US US12/170,393 patent/US20090170197A1/en not_active Abandoned

Publication	Publication Date	Title
JP2000500228A5 (2)	2004-09-09
JP2000500033A5 (2)	2004-09-09
JP2000504925A5 (2)	2004-10-14
JPH11514474A5 (2)	2004-10-14
JP2000500327A5 (2)	2005-10-06
JP2000500145A5 (2)	2004-10-14
JP2000500155A5 (2)	2004-10-21
JP2000500406A5 (2)	2004-10-14
JP2000500361A5 (2)	2004-10-14
JPH11510206A5 (2)	2004-09-09
JP2000500322A5 (2)	2004-09-30
JP2000500258A5 (2)	2004-08-12
JP2000500342A5 (2)	2004-10-21
JP2000500192A5 (2)	2004-07-15
JP2000500226A5 (2)	2004-08-12
JP2000500051A5 (2)	2004-10-14
JP2000500407A5 (2)	2004-10-21
JP2000500397A5 (2)	2004-10-21
JP2000500166A5 (2)	2004-09-24
JP2000500019A5 (2)	2004-11-04
JP2000500125A5 (2)	2004-10-21
JP2000500346A5 (2)	2005-06-16
JP2000500044A5 (2)	2006-01-05
JP2000500090A5 (2)	2005-11-24
JP2000500257A5 (2)	2004-08-12